Skip to main content
Neurology

Eligibility and Safety Considerations for Antiamyloid Alzheimer Therapies

In this fourth episode, Sharon Cohen, MD, FRCPC, talked about key differences between lecanemab and donanemab in terms of eligibility requirements to the receive the treatment. Supported by Eli Lilly.:

Source: Neurology Read More

Related Posts

Neurology <![CDATA[Pariceract Fails to Meet Primary End point in Phase 2b ACTIVATE Trial for GBA1-Associated Parkinson Disease]]>

<![CDATA[Pariceract Fails to Meet Primary End point in Phase 2b ACTIVATE Trial for GBA1-Associated Parkinson Disease]]>

June 12, 2026
Neurology <![CDATA[3-Year ENLIGHTEN Analysis Links Lower Neurofilament Light Chain Levels to Improved Cognition in Early MS: John DeLuca, PhD]]>

<![CDATA[3-Year ENLIGHTEN Analysis Links Lower Neurofilament Light Chain Levels to Improved Cognition in Early MS: John DeLuca, PhD]]>

June 12, 2026
Neurology <![CDATA[Extending the Treatment Window for Thrombolysis in Acute Ischemic Stroke: Fan Z. Caprio, MD]]>

<![CDATA[Extending the Treatment Window for Thrombolysis in Acute Ischemic Stroke: Fan Z. Caprio, MD]]>

June 11, 2026